- Home
- PSNL vs TIL Comparison
PSNL vs TIL Comparison
Compare PSNL & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSNL | TIL |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 177.1M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PSNL | TIL |
|---|---|---|
| Price | $8.97 | $10.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $10.71 | ★ $100.67 |
| AVG Volume (30 Days) | ★ 1.6M | 72.7K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,103,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.83 | $10.70 |
| 52 Week High | $11.40 | $42.79 |
Technical Indicators
Market Signals| Indicator | PSNL | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 36.08 |
| Support Level | $9.34 | $10.76 |
| Resistance Level | $9.85 | $11.51 |
| Average True Range (ATR) | 0.70 | 0.73 |
| MACD | -0.15 | 0.16 |
| Stochastic Oscillator | 2.17 | 2.71 |
Price Performance
Historical ComparisonAbout PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.